Trastuzumab Deruxtecan in Patients With HER2+ Advanced/Metastatic Breast Cancer With or Without Brain Metastases: DESTINY-Breast12 Primary Results

Dr. Sara A. Hurvitz presents the primary results from the DESTINY-Breast12 trial, highlighting the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive advanced/metastatic breast cancer, including those with stable or active brain metastases​.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
x